Trump Says 'Major Tariff on Pharmaceuticals' Coming Soon
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
Improved Revenues Required Before ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock's 25% Jump Looks Justified
Jefferies Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $80
Strong Growth and Undervaluation Make ANI Pharmaceuticals a Buy
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN and YUTIQ
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $94
New York Manufacturing Hits Low, Inflation Fears Rise
HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target
Insider Sale: SR. VP of $ANIP Sells 400 Shares
This Insider Has Just Sold Shares In ANI Pharmaceuticals
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
Sector Update: Health Care Stocks Higher Premarket Friday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Reduced Government Shutdown Risk